CMV remains an important complication for allo-SCT. CMV can cause disease in several different organs after SCT including pneumonia, hepatitis, gastroenteritis, retinitis and encephalitis. Seropositivity of the patients remains even in 2007 a major risk factor for TRM in unrelated SCT patients. Seronegative patients with seropositive stem cell donors develop primary CMV infection in about 30% and have an increased mortality in bacterial and fungal infections. 1 Other identified risk factors include acute and chronic GVHD and the use of mismatched or unrelated donors. In a study using the EBMT registry, CMVseropositive patients receiving seropositive unrelated donor grafts had improved survival and reduced TRM compared with those receiving seronegative grafts, and a similar result was found in a single center study.
2 Other studies have, however, failed to find this correlation so that the effect on mortality remains controversial.
3 However, this serological combination has also been associated with late development of specific immunity, repeated CMV reactivations, and an increased risk for the development of CMV retinitis.
As the prognosis of established CMV disease is still poor, preventive measures are very important. The available strategies can be divided into prevention of a primary infection or recurrence of CMV (prophylaxis) or prevention of development of disease when a reactivation has occurred (preemptive therapy). Patients who are CMV seronegative before SCT should, if possible, be transplanted from a CMV-seronegative donor, and 'CMV-safe' blood products should be used.
4-7 I.v. Ig has at best a minor effect. Highdose acyclovir and valacyclovir can reduce the risk for CMV infection, 8, 9 and valacyclovir can reduce the need for preemptive therapy to approximately 50%. 9 I.v. ganciclovir is effective for prevention of CMV disease but has been associated with significant toxicity and is today infrequently used. Valganciclovir is the prodrug of ganciclovir giving similar blood levels as i.v ganciclovir, but no study has evaluated its efficacy as a prophylactic agent. A new drug, maribavir, has shown promise as a prophylactic agent and a phase III trial is ongoing. 10 Recently, sirolimus as prophylaxis against acute GVHD has been reported to result in a lower risk for CMV reactivation. 11 Preemptive therapy based on early detection of CMV has become the most commonly used strategy for the prevention of CMV disease after allo-SCT. 12 As early identification of patients with CMV infection reduces virus-related morbidity and mortality, monitoring with antigenemia or quantitative PCR is indicated in allo-SCT patients. Ganciclovir is the most used drug. Although foscarnet is as effective as ganciclovir, 12 it is more commonly today used as a secondline drug. Valganciclovir has been studied in uncontrolled studies and in two small randomized pharmacokinetic studies. 13 Resistance to antiviral therapy is quite rare in SCT patients and increasing antigenemia or CMV DNA early after initiation of antiviral therapy is usually not a sign of antiviral resistance and does not necessitate change of therapy. 14, 15 Cidofovir is an alternative as a second-line agent 16, 17 and, recently, case reports have been published of treatment with leflunomide or artesunate in patients failing other antiviral therapy. [18] [19] [20] The prognosis in patients with established CMV disease is still poor. 21 The standard therapy for CMV pneumonia has been i.v. ganciclovir combined with high-dose Ig, but this standard has never been evaluated in a controlled study and more recent studies have questioned whether the addition of Ig improves outcome. 22 For patients with CMV disease other than pneumonia, the addition of Ig does not seem to be beneficial.
The lack of specific immunity to CMV both regarding CTL response and helper T-cell response to CMV has been associated with a high risk for CMV disease. 21, 23, 24 Monitoring of CD8 and/or CD4 CMV-specific T cells has, therefore, been studied, and different techniques can be applied including detection by tetramers containing immunodominant peptides from CMV or measurement of peptide-specific intracellular cytokine staining. [25] [26] [27] [28] Techniques for collecting and expanding CMV-specific T cells including the use of peptide-pulsed dendritic cells, selection by tetramer technology or vaccination with peptide-pulsed dendritic cells have been developed, and several centers are testing these strategies in clinical trials.
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